+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Disease Therapeutics Market by Drug Class, Route of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Infectious Disease Therapeutics Market by Drug Class, Route of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Infectious Disease Therapeutics Market by Drug Class, Route of Administration, Indication, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888743
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infectious Disease Therapeutics Market grew from USD 121.27 billion in 2024 to USD 126.80 billion in 2025. It is expected to continue growing at a CAGR of 4.43%, reaching USD 157.36 billion by 2030.

Opening New Frontiers in Infectious Disease Therapeutics

The landscape of infectious disease therapeutics sits at an unprecedented crossroads. Scientific breakthroughs in molecular biology and immunology are converging with evolving patterns of antimicrobial resistance, challenging industry stakeholders to redefine conventional approaches. As global health systems grapple with the dual pressures of emerging pathogens and the resurgence of familiar threats, the demand for innovative drug classes and delivery methods intensifies. This executive summary sets the stage for a rigorous exploration of market dynamics, regulatory shifts, and competitive forces that will shape the trajectory of antibiotics, antifungals, antivirals, biologics, and vaccines. By establishing a clear contextual foundation, this introduction frames the multifaceted challenges and opportunities inherent in combating infectious diseases. It underscores the imperative for agile strategies that can respond to rapid scientific progress and geopolitical influences. Through this lens, decision-makers will gain an integrated perspective on the key drivers propelling research investments, shaping policy reforms, and redefining patient care paradigms. Ultimately, the opening section invites stakeholders to engage deeply with the analysis that follows, preparing them to navigate the complexities and capitalize on the transformative trends ahead.

Transformative Forces Reshaping Infectious Disease Treatment

Over the past several years, the infectious disease domain has undergone profound transformation, fueled by breakthroughs in genomic sequencing and the advent of targeted therapies. Novel antibiotic scaffolds are emerging from advanced screening platforms, while antifungal drug discovery leverages structural biology to overcome long-standing efficacy barriers. Meanwhile, the antiviral landscape has been revolutionized by integrase inhibitors and protease inhibitors that offer unprecedented specificity against viral replication pathways. In parallel, biologics such as monoclonal antibodies and cytokine therapies are extending treatment horizons beyond traditional small molecules. Vaccine technology has also leaped forward with the success of subunit and conjugate platforms, accelerating the transition to next-generation immunization strategies. Furthermore, the increasing integration of digital health tools and real-world evidence is reshaping clinical trial design and post-market surveillance. Collectively, these shifts are redefining therapeutic development timelines, cost structures, and regulatory frameworks. This section illuminates the drivers behind these transformative trends and explores how they converge to create a dynamic, opportunity-rich environment for developers, payers, and healthcare providers alike.

Assessing the Cumulative Impact of US Tariffs on Therapeutics

The implementation of new tariff measures in 2025 has introduced a layer of complexity to the supply chain for critical therapeutics. Increased duties on raw pharmaceutical ingredients and finished drug products are impacting production costs and forcing manufacturers to reassess sourcing strategies. Companies that historically relied on cross-border procurement of active pharmaceutical ingredients are now evaluating localized manufacturing to mitigate tariff exposure. This strategic pivot, while enhancing supply resilience, demands significant capital investment and operational restructuring. At the same time, downstream stakeholders such as distributors and healthcare facilities are feeling the ripple effects of elevated pricing pressures. In response, some market participants are initiating collaborative procurement models to spread cost burdens more equitably. Regulatory authorities are also addressing potential access gaps by fast-tracking approval processes for domestically produced compounds. As a result, the tariff landscape is catalyzing a broader realignment of production networks, supply agreements, and regulatory partnerships. This section provides an in-depth examination of how the 2025 tariff regime is influencing manufacturing footprints, pricing strategies, and the overall architecture of the therapeutics value chain.

Dissecting Market Segments for Targeted Strategic Insights

Analyzing the market through the lens of drug class reveals distinct growth trajectories. Antibiotics, broken down into aminoglycosides, beta lactams, fluoroquinolones, macrolides, and tetracyclines, continue to represent a foundational pillar, yet face mounting resistance challenges. Antifungals built on azole, echinocandin, and polyene frameworks are gaining traction as clinicians prioritize options with improved safety profiles. The antiviral segment, encompassing integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, and protease inhibitors, has been invigorated by sustained R&D investments aimed at emerging viral threats. Biologics, led by cytokines and monoclonal antibodies, are driving high-value growth, particularly in complex infection management. Vaccine innovation across conjugate, inactivated, live attenuated, and subunit platforms underscores preventive strategies as a cost-effective complement to therapeutics. When viewed by route of administration, intravenous formulations dominate acute care settings, while inhalation and topical options are expanding in outpatient protocols. Oral therapies retain a critical role in chronic infection management, supported by adherence-enhancing drug design. In terms of indication, COVID-19 catalyzed rapid product development, but gastrointestinal infections, hepatitis, HIV/AIDS, respiratory infections, skin infections, and urinary tract infections continue to command significant clinical focus. Distribution channels ranging from hospital pharmacies to online and retail pharmacies illustrate evolving patient access models. Finally, the segmentation by end users-clinics, homecare, and hospitals-highlights where demand is intensifying and resource allocation becomes paramount. This comprehensive segmentation insight equips stakeholders to tailor strategies that align with the unique characteristics of each segment.

Regional Dynamics Influencing Therapeutic Adoption

Regional dynamics are critically shaping the adoption and commercialization of infectious disease therapeutics. In the Americas, well-established healthcare infrastructure and high per capita spending foster rapid uptake of novel therapies, yet the region grapples with disparities in access among underserved populations. Europe, Middle East & Africa present a mosaic of regulatory environments, where robust markets in Western Europe coexist alongside emerging economies that demand cost-effective formulations and adaptive pricing models. Meanwhile, Asia-Pacific has become a hotbed for manufacturing scale-up and clinical trial activity, driven by expanding healthcare coverage and government-backed innovation initiatives. These diverse regional drivers influence investment priorities and partnership strategies; for instance, technology transfer agreements are accelerating in Asia-Pacific, while Europe is witnessing a surge in public-private collaborations to address antimicrobial resistance. Across all regions, policymakers are increasingly focused on improving supply chain resilience, refining reimbursement frameworks, and incentivizing R&D in areas of unmet medical need. By unpacking these regional nuances, stakeholders can tailor entry strategies, align with local regulatory landscapes, and optimize resource deployment to maximize market impact.

Spotlight on Leading Innovators and Market Drivers

The competitive landscape is anchored by several global players and emerging innovators. Longstanding pharmaceutical companies are leveraging scale and regulatory expertise to sustain leadership in core antibiotic and antiviral franchises. At the same time, specialized biotech firms are disrupting the status quo with next-generation biologics and vaccine candidates that address resistant pathogens and niche indications. Strategic alliances between large-cap organizations and agile biotech start-ups are streamlining development pipelines and accelerating time-to-market. Additionally, contract manufacturing organizations are playing an instrumental role in scaling production for complex molecules, often serving as gatekeepers to capacity expansions. In parallel, digital health companies are integrating diagnostic solutions to complement therapeutic portfolios, enabling precision treatment approaches. Investor interest in the space has escalated, driving a wave of mergers, acquisitions, and licensing deals aimed at bolstering pipelines and geographic reach. This convergence of established incumbents and innovative newcomers, coupled with cross-sector partnerships, is reshaping the contours of competition and collaboration within the infectious disease therapeutics sector.

Strategic Imperatives for Industry Leadership

Industry leaders must embrace a multifaceted strategy to navigate the evolving landscape effectively. Priority should be placed on forging resilient supply chains by diversifying manufacturing footprints and establishing regional production hubs. Investing in antimicrobial stewardship programs and real-world evidence generation will enhance market access and inform value-based pricing negotiations. Collaborative R&D initiatives with academic institutions and biotech firms can accelerate the discovery of novel mechanisms of action, particularly in areas of high unmet need. In parallel, integrating companion diagnostics and digital health platforms will bolster personalized treatment strategies and improve patient outcomes. Strategic engagement with regulatory bodies to advocate for adaptive approval pathways can shorten development timelines and reduce uncertainty. Furthermore, targeting underserved regional markets through tailored access programs will unlock new revenue streams while advancing global health equity. By implementing these strategic imperatives, industry participants can achieve sustainable growth and reinforce their leadership in combating infectious diseases.

Rigorous Approach Ensuring Robust Market Analysis

This analysis is underpinned by a rigorous, multi-source research framework. Primary inputs included in-depth interviews with senior executives, clinical experts, and supply chain specialists across major pharmaceutical and biotech organizations. Secondary sources comprised peer-reviewed journals, regulatory filings, industry white papers, and market intelligence databases. Data triangulation techniques were employed to reconcile disparate data points, ensuring high confidence in the findings. Quantitative analyses such as thematic trend mapping and scenario impact assessment were complemented by qualitative insights derived from expert panels. The methodological approach adhered to stringent quality control protocols, including peer reviews and verification against external benchmarks. Geographic and segmental coverage was calibrated to reflect the diversity of market conditions across global regions and therapeutic categories. By combining robust data collection, rigorous validation, and transparent documentation, this methodology delivers a dependable foundation for strategic decision-making in the infectious disease therapeutics arena.

Converging Insights and Pathways Forward

The convergence of scientific innovation, regulatory evolution, and geopolitical forces presents both opportunities and challenges for stakeholders in infectious disease therapeutics. By examining transformative shifts, tariff impacts, segment-specific dynamics, and regional nuances, this executive summary has illuminated the critical factors driving market behavior. Leading companies are already leveraging these insights to refine pipelines, optimize supply chains, and pursue strategic partnerships. Yet the path forward requires continued vigilance in antimicrobial stewardship, adaptive business models that anticipate policy changes, and ongoing investment in high-impact R&D. As the global community strives to combat existing and emerging pathogens, the ability to translate data-driven insights into actionable strategies will define success. This synthesis underscores the importance of an integrated perspective-one that aligns innovation, access, and sustainability-to shape the future of infectious disease treatment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Antibiotics
      • Aminoglycosides
      • Beta Lactams
      • Fluoroquinolones
      • Macrolides
      • Tetracyclines
    • Antifungals
      • Azoles
      • Echinocandins
      • Polyenes
    • Antivirals
      • Integrase Inhibitors
      • Neuraminidase Inhibitors
      • Nucleoside Analogues
      • Protease Inhibitors
    • Biologics
      • Cytokines
      • Monoclonal Antibodies
    • Vaccines
      • Conjugate
      • Inactivated
      • Live Attenuated
      • Subunit
  • Route Of Administration
    • Inhalation
    • Intravenous
    • Oral
    • Topical
  • Indication
    • COVID-19
    • Gastrointestinal Infections
    • Hepatitis
    • HIV/AIDS
    • Respiratory Infections
    • Skin Infections
    • Urinary Tract Infections
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Clinics
    • Homecare
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • AstraZeneca plc
  • AbbVie Inc.
  • Novartis AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Infectious Disease Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Antibiotics
8.2.1. Aminoglycosides
8.2.2. Beta Lactams
8.2.3. Fluoroquinolones
8.2.4. Macrolides
8.2.5. Tetracyclines
8.3. Antifungals
8.3.1. Azoles
8.3.2. Echinocandins
8.3.3. Polyenes
8.4. Antivirals
8.4.1. Integrase Inhibitors
8.4.2. Neuraminidase Inhibitors
8.4.3. Nucleoside Analogues
8.4.4. Protease Inhibitors
8.5. Biologics
8.5.1. Cytokines
8.5.2. Monoclonal Antibodies
8.6. Vaccines
8.6.1. Conjugate
8.6.2. Inactivated
8.6.3. Live Attenuated
8.6.4. Subunit
9. Infectious Disease Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Inhalation
9.3. Intravenous
9.4. Oral
9.5. Topical
10. Infectious Disease Therapeutics Market, by Indication
10.1. Introduction
10.2. COVID-19
10.3. Gastrointestinal Infections
10.4. Hepatitis
10.5. HIV/AIDS
10.6. Respiratory Infections
10.7. Skin Infections
10.8. Urinary Tract Infections
11. Infectious Disease Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Infectious Disease Therapeutics Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare
12.4. Hospitals
13. Americas Infectious Disease Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Infectious Disease Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Infectious Disease Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Gilead Sciences, Inc.
16.3.3. Johnson & Johnson
16.3.4. F. Hoffmann-La Roche Ltd
16.3.5. Merck & Co., Inc.
16.3.6. GlaxoSmithKline plc
16.3.7. Sanofi S.A.
16.3.8. AstraZeneca plc
16.3.9. AbbVie Inc.
16.3.10. Novartis AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. INFECTIOUS DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. INFECTIOUS DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 78. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 80. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 81. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 82. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 83. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 84. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 94. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 141. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 142. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 143. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 144. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 145. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 153. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 154. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 155. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 171. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 172. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 173. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 174. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 175. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 181. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 182. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 183. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 184. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 185. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 221. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 222. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 223. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 224. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 225. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 241. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 242. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 243. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 244. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 245. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 251. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 252. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 253. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 254. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 255. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 257. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 262. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 263. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 264. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 281. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 282. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 283. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 284. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 285. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 287. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 290. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 291. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 292. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 293. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 294. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 295. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL INFECTIOUS DISEASE THERAP

Companies Mentioned

The companies profiled in this Infectious Disease Therapeutics market report include:
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • AstraZeneca plc
  • AbbVie Inc.
  • Novartis AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 126.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 157.36 Billion
Compound Annual Growth Rate4.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Infectious Disease Therapeutics Market Size, Share & Trends Analysis Report By Infection (Bacterial, Viral), By Drug Class (Antibacterial, Antiviral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Infectious Disease Therapeutics Market Size, Share & Trends Analysis Report By Infection (Bacterial, Viral), By Drug Class (Antibacterial, Antiviral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Infectious Disease Therapeutics - Global Strategic Business Report - Product Image

Infectious Disease Therapeutics - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Infectious Disease Therapeutics Market Report 2025 - Product Image

Infectious Disease Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration and Distribution Channel - Product Image

Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration and Distribution Channel

  • Report
  • 101 Pages
  • Asia Pacific
From
Europe Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration and Distribution Channel - Product Image

Europe Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration and Distribution Channel

  • Report
  • 106 Pages
  • Europe
From

About the Infectious Disease Drug Market

The Infectious Disease Drug market is a subset of the pharmaceutical industry that focuses on the development and production of drugs to treat infectious diseases. These drugs are used to treat a wide range of illnesses, from bacterial and viral infections to fungal and parasitic diseases. The market is highly competitive, with many companies vying for market share. Companies in the market are typically focused on developing new drugs, as well as improving existing treatments. They also work to ensure that their drugs are safe and effective. Some of the major players in the Infectious Disease Drug market include Pfizer, Merck, GlaxoSmithKline, Sanofi, Johnson & Johnson, and AstraZeneca. These companies are involved in the research, development, and production of drugs to treat a variety of infectious diseases. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.